Oculus Innovative Sciences, Inc., has launched Microcyn Wound Care product into the U.S. podiatry market. The product has received three FDA 510(k) clearances for use in moistening, lubricating, cleaning and debriding wounds. It is available to podiatrists for treatment of, and distribution to, their patients in 8 oz. and 500 ml. bottles. Oculus is also pursuing a U.S. drug approval using a different formulation of the Microcyn Technology. The company intends to secure a partner that will assume clinical, regulatory, and commercial responsibilities along with costs for the drug formulation approval.

Smith & Nephew’s Advanced Wound Management division has announced the launch of its new product, ACTICOAT Flex, to expand the ACTICOAT range. Designed to support physicians dealing with injuries at high risk of infection, the product utilizes the Silcryst(R) nano-crystalline silver technology. It is highly conformable – ideal for awkward anatomical areas such as face and hands to improve patient comfort during wear. The product will be available in the markets of USA and EU by early 2009.

The U.S. Food and Drug Administration has granted 510(k) clearance to Ivera Medical Corporation, allowing it to market its Curos™ Port Protector. The product decontaminates needle-less intravenous access ports, preventing touch and airborne contamination. Designed to lessen patients’ exposure to the risks of bloodstream infections acquired from hospitals, the Curos Port Protector facilitates infection control. Such infections lengthen a patient’s stay in hospital and can be dangerous too. Thus, the device can be really useful in improving patient care through promotion among healthcare professionals.